ABC | Volume 113, Nº1, Julho 2019

Posicionamento Posicionamento sobre Indicações da Ecocardiografia em Adultos – 2019 Arq Bras Cardiol. 2019; 113(1):135-181 87. Qasem M, Utomi V, George K, Somauroo J, Zaidi A, Forsythe L, et al. A meta-analysis for echocardiographic assessment of right ventricular structure and function in ARVC. Echo Res Pract. 2016;3(3):95–104. 88. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/ dysplasia:proposed modification of the Task Force Criteria. Eur Heart J. 2010;31(7):806-14. 89. Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy-an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(3):237-53. 90. Maron BJ, Towbin JA, ThieneG, Antzelevitch C, CorradoD, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee;Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16. 91. Paterick TE, Umland MM, Jan MF, Ammar KA, Kramer C, Khandheria BK, et al. Left ventricular noncompaction:a 25-year odyssey. J Am Soc Echocardiogr. 2012;25(4):363-75. 92. C h e b r o l u LH , Me h t a AM , Na n d a NC . No n c omp a c t i o n cardiomyopathy:The role of advancedmultimodality imaging techniques in diagnosis and assessment. Echocardiography. 2017;34(2):279-89. 93. Rosa LV, Salemi VM, Alexandre LM, Mady C. Noncompaction cardiomyopathy:a current view. Arq Bras Cardiol. 2011;97(1):e13-9. 94. Gati S, Rajani R, Carr-White GS, Chambers JB. Adult left ventricular noncompaction:reappraisal of current diagnostic imaging modalities. JACC Cardiovasc Imaging. 2014;7(12):1266-75. 95. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the Use of Echocardiography in Adult Hypertension:A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28(7):727-54. 96. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy:novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol. 2007;34(4):255-62. 97. Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation. 1990;81(3):1144-6. 98. Liebson PR, Grandits G, Prineas R, Dianzumba S, Flack JM, Cutler JA, et al. Echocardiographiccorrelatesof leftventricularstructureamong844mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993;87(2):476-86. 99. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults:an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14. 100. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, BohmM, et al. 2013ESH/ESCGuidelines forthemanagementofarterialhypertension:the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. 101. Kishi S, Teixido-Tura G, Ning H, Venkatesh BA, Wu C, Almeida A, et al. Cumulative Blood Pressure in Early Adulthood andCardiacDysfunction in Middle Age:The CARDIA Study. J AmColl Cardiol. 2015;65(25):2679-87. 102. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50-103. 103. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345-52. 104. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension:the MAVI study. J Am Coll Cardiol. 2001;38(7):1829-35. 105. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function;epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43(3):317-27. 106. Sharp AS, Tapp RJ, Thom SA, Francis DP, Hughes AD, Stanton AV, et al. Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population:an ASCOT substudy. Eur Heart J. 2010;31(6):747-52 107. Galderisi M, Lomoriello VS, Santoro A, Esposito R, Olibet M, Raia R, et al. Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives:a speckle-tracking echocardiography study. J Am Soc Echocardiogr. 2010;23(11):1190-8. 108. Saito M, Khan F, Stoklosa T, Iannaccone A, Negishi K, Marwick TH. Prognostic implicationsofLVstrainriskscore inasymptomaticpatientswith hypertensive heart disease. JACCCardiovasc Imaging. 2016;9(8):911-21. 109. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens. 2008;21(4):464-70. 110. Wachtell K, Palmieri V, OlsenMH, Gerdts E, Papademetriou V, Nieminen MS, et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment:the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002;106(2):227-32. 111. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlof B, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment:The Losartan Intervention For Endpoint Reduction inHypertension (LIFE)Study.Circulation.2002;105(9):1071-6. 112. Palmieri V, Bella JN, Arnett DK, Roman MJ, Oberman A, Kitzman DW, et al. Aortic root dilatation at sinuses of valsalva and aortic regurgitation in hypertensive and normotensive subjects:The Hypertension Genetic Epidemiology Network Study. Hypertension. 2001;37(5):1229-35. 113. Teixido-Tura G, Almeida AL, Choi EY, Gjesdal O, Jacobs DR Jr, Dietz HC, et al. Determinants of aortic root dilatation and reference values among young adults over a 20-year period:coronary artery risk development in young adults study. Hypertension. 2015;66(1):23-9. 114. Maron BJ, Epstein SE, RobertsWC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986;7(1):204-14. 115. Caselli S, MaronMS, Urbano-Moral JA, PandianNG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014;114(9):1383-9. 116. Caselli S, Montesanti D, Autore C, Di Paolo FM, Pisicchio C, SqueoMR, et al. Patterns of left ventricular longitudinal strain and strain rate inOlympic athletes. J Am Soc Echocardiogr. 2015;28(2):245-53. 117. Caselli S, Di Paolo FM, Pisicchio C, PandianNG,Pelliccia A. Patterns of left ventricular diastolic function inOlympic athletes. J Am Soc Echocardiogr. 2015;28(2):236-44. 118. Maron BJ. Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification. Cardiol Clin. 2007;25(3):399-414, vi. 119. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes:2007 update:ascientificstatement fromtheAmericanHeartAssociationCouncil 176